Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389214 | 0.90 | FFAR4 (0.42) | SCN9AHCRTR1HCRTR2C5AR1HSD11B1 | |
| SCHEMBL27844879 | 0.85 | SCN9A (0.41) | SCN9AHCRTR1HCRTR2C5AR1SSTR1 | |
| SCHEMBL12056861 | 0.81 | TNF (0.47) | GAACYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL388488 | 0.78 | SCN9A (0.37) | SCN9AAVPR2AVPR1A | |
| SCHEMBL718717 | 0.77 | MDM2 (0.39) | SCN9AHCRTR1HCRTR2HSD11B1 | |
| SCHEMBL8227969 | 0.76 | POLB (0.49) | GAACYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL8233387 | 0.74 | NLRP3 (0.48) | CYP1A2GAACYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL4511121 | 0.74 | NPC1 (0.47) | AVPR2AVPR1A | |
| SCHEMBL8233607 | 0.72 | RXFP1 (0.42) | AVPR2AVPR1A | |
| SCHEMBL8232452 | 0.72 | RXFP1 (0.45) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408754-B1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN RECEPTOR FOR THE TREATMENT OF CARDIAC INSUFFICIENCY | BAYER IP GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-20120053218-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053218-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2010105750-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053218-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | AVPR2, AVPR1B, AVPR1A | SCN9A 3271/4885HCRTR1 835/4885HCRTR2 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.